EU CRD definition

EU CRD means: (i) Regulation (EU) No 575/2013 of the European Parliament and of the Council of 26 June 2013 on prudential requirements for credit institutions and investments firms, as amended before IP completion day; and (ii) Directive 2013/36/EU of the European Parliament and of the Council of 26 June 2013 on access to the activity of credit institutions and the prudential supervision of credit institutions and investment firms, amending Directive 2002/87/EC and repealing Directives 2006/48/EC and 2006/49/EC, as amended before IP completion day.
Sample 1Sample 2Sample 3
EU CRD means the Capital Requirements Directive; EU CRR means Regulation (EU) No. 575/2013 referred to as Capital Requirements Regulation; EU Data Protection Laws means any law, enactment, regulation or order transposing, implementing, adopting, supplementing or derogating from, the EU GDPR and the EU Directive 2002/58/EC in each member state of the European Union; EU EMIR or the EU European Market Infrastructure Regulation means Regulation (EU) No. 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties and trade repositories dated 4 July 2012 (including, without limitation, any associated regulatory technical standards and advice, guidance or recommendations from relevant supervisory regulators); EU GDPR means Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation); EU MiFID II means Directive 2014/65/EU on markets in financial instruments; EU Prospectus Regulation means Regulation (EU) 2017/1129; EU Securitisation Regulation means Regulation (EU) 2017/2402 as amended, varied, superseded or substituted from time to time;
Sample 1

Examples of EU CRD in a sentence

  • One way to decrease the interest rate risk for a longer term loan is to set the interest rate to a floating or adjustable short-term rate.

  • CX/CF 10/4/6-Add.1 (comments of Argentina and Norway); CX/CF 10/4/6-Add.2 (comments of Japan); CRD 4 (comments of Kenya); CRD 5 (comments of Iran); CRD 9 (comments of the EU); CRD 14 (comments of Bolivia); CRD 22 (comments of Ecuador).

  • This document sets out disclosures in respect of East-West United Bank S.A. (EWUB) required under European Union (EU) CRD IV legislation, consisting of the Capital Requirements Regulation (CRR) and the Capital Requirements Directive (CRD).

  • Additional comments from the EU (CRD 9); Mexico (CRD 10); Philippines (CRD 12); Egypt (CRD 15); Ghana (CRD 17); and Kenya (CRD 20).

  • Additional comments from the EU (CRD 9); Mexico (CRD 10); Egypt (CRD 15); Peru (CRD 19); Kenya (CRD 20); and Turkey (CRD 22).

  • This document sets out disclosures in respect of the consolidated group comprising Mizuho International plc (MHI) and Mizuho Securities Europe GmbH (MHEU), together “the Group”, required under European Union (EU) CRD legislation, consisting of the Capital Requirements Regulation1 (CRR) and the Capital Requirements Directive2 (CRD).

  • Additional comments from Iran (CRD 8); EU (CRD 9); Mexico (CRD 10); Kenya (CRD 20); Thailand (CRD 14); and Turkey (CRD 22).

  • AXA Bank Europe is subject to the large exposures limit framework described in articlesIII.4 & III.5 of the CBFA circular 2007-1- CPB, transposed from articles 106-119 of the EU CRD and updated in 2011 with circular letter CBFA_2011_03 dated 27 January 2011.

  • EU CRD – Qualitative disclosure requirements on institutions’ use of external credit ratings under the standardised approach for credit risk Article 444(a) Mapping of ECAIs’ credit assessments and credit quality steps (CQS) EU CR4 – Standardised approach – Credit risk exposure and CRM effects The table below illustrates the effect of all CRM techniques applied in accordance with the CRR.

  • Based on the European Directive 2013/36/ EU (CRD) and the guidelines of the European Banking Authority (EBA), the Bank is required to assess the adequacy of its liquidity risk management processes andthe degree to which its pool of liquid assets is commensurate with the profile and risk appetite of its Board of Directors.

Related to EU CRD

  • EU GDPR means Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC.

  • EUWA means the European Union (Withdrawal) Act 2018, as amended.

  • EUA or “Extended Use Agreement” means, with respect to the HC Program, an agreement which sets forth the set-aside requirements and other Development requirements under the HC Program.

  • Approved clinical trial means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or Condition and is described in any of the following:

  • CFDA means the Code of Federal Domestic Assistance assigned to a federal grant.

  • ICH GCP means the ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) together with such other good clinical practice requirements as are specified in Directive 2001/20/EC of the European Parliament and the Council of 4 April 2001 relating to medicinal products for human use and in guidance published by the European Commission pursuant to such Directive.

  • EU means the European Union.

  • Clinical evaluation means a systematic and planned process to continuously generate, collect, analyse and assess the clinical data pertaining to a device in order to verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer;

  • spatial development framework means the Mhlontlo Municipal Spatial Development Framework prepared and adopted in terms of sections 20 and 21 of the Act and Chapter 2 of this By-Law;

  • CEQA means the California Environmental Quality Act (Cal. Public Resources Code Sections 21000 et seq.) and the State CEQA Guidelines (Cal. Code of Regs., Title 14, Sections 15000 et seq.).

  • Licensed clinical social worker means an individual who meets the licensed clinical social worker requirements established in KRS 335.100.

  • Environmental and Social Management Framework or “ESMF” means the framework included in the EA setting out modalities to be followed in assessing the potential adverse environmental and social impact associated with activities to be implemented under the Project, and the measures to be taken to offset, reduce, or mitigate such adverse impact.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Pivotal Clinical Trial means a human clinical trial in any country that is prospectively designed to generate data intended to satisfy the requirements of 21 C.F.R. § 312.21(c) (as amended) in the U.S. or a similar clinical study prescribed by a Regulatory Authority from another country, from time to time, pursuant to Applicable Law.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • MFDA means the Mutual Fund Dealers Association of Canada;

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • GCP means the Good Clinical Practices officially published by EMA, FDA and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) that may be in effect from time to time and are applicable to the testing of the Compounds.

  • Mobile crisis outreach team means a crisis intervention service for minors or families of minors experiencing behavioral health or psychiatric emergencies.

  • Phase III Clinical Trial means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.

  • NZOC means the New Zealand Olympic Committee Incorporated.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Clinical review criteria means the written screening procedures, decision abstracts, clinical protocols, and practice guidelines used by a health carrier to determine the necessity and appropriateness of health care services.

  • Global Development Plan has the meaning set forth in Section 3.1.